HK1201176A1 - Antigen presenting cancer vaccine - Google Patents

Antigen presenting cancer vaccine Download PDF

Info

Publication number
HK1201176A1
HK1201176A1 HK15101637.0A HK15101637A HK1201176A1 HK 1201176 A1 HK1201176 A1 HK 1201176A1 HK 15101637 A HK15101637 A HK 15101637A HK 1201176 A1 HK1201176 A1 HK 1201176A1
Authority
HK
Hong Kong
Prior art keywords
cells
gamma
antigen presenting
cancer vaccine
melanoma
Prior art date
Application number
HK15101637.0A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew CORNFORTH
Robert DILLMAN
Original Assignee
Neostem Oncology, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neostem Oncology, Llc filed Critical Neostem Oncology, Llc
Publication of HK1201176A1 publication Critical patent/HK1201176A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15101637.0A 2011-10-20 2012-10-22 Antigen presenting cancer vaccine HK1201176A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161549681P 2011-10-20 2011-10-20
US61/549,681 2011-10-20
US201261594304P 2012-02-02 2012-02-02
US61/594,304 2012-02-02
PCT/US2012/061306 WO2013059784A1 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine

Publications (1)

Publication Number Publication Date
HK1201176A1 true HK1201176A1 (en) 2015-08-28

Family

ID=48141460

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15101637.0A HK1201176A1 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine
HK15101635.2A HK1201175A1 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15101635.2A HK1201175A1 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon

Country Status (11)

Country Link
US (2) US9555058B2 (OSRAM)
EP (2) EP2768519A4 (OSRAM)
JP (2) JP2014530627A (OSRAM)
KR (2) KR20150016200A (OSRAM)
CN (5) CN105288602A (OSRAM)
AU (2) AU2012325764A1 (OSRAM)
CA (2) CA2852960A1 (OSRAM)
HK (2) HK1201176A1 (OSRAM)
IL (2) IL232173A0 (OSRAM)
SG (4) SG11201401631VA (OSRAM)
WO (2) WO2013059784A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865830B1 (fr) 2004-01-30 2006-05-19 Neopost Ind Systeme d'affranchissement de courrier a mode d'impression externe securise
CN105288602A (zh) 2011-10-20 2016-02-03 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
JP6967963B2 (ja) * 2014-07-17 2021-11-17 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法
KR20180126085A (ko) * 2016-05-05 2018-11-26 난토믹스, 엘엘씨 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor)
CA3053939A1 (en) * 2017-02-17 2018-08-23 Aivita Biomedical, Inc. Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells
WO2024107624A1 (en) * 2022-11-14 2024-05-23 Shattuck Labs, Inc. Methods of overcoming resistance to checkpoint inhibitor therapies
CN118441033B (zh) * 2024-04-24 2025-06-20 广西医科大学 HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598998B1 (en) * 1992-09-07 2004-05-19 Kyowa Hakko Kogyo Co., Ltd Humanized antibodies reacting with the ganglioside GM2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
CA2321093A1 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
AU8026800A (en) 1999-10-15 2001-04-30 Baylor Research Institute Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
DK1448229T3 (da) * 2001-11-29 2010-03-08 Dandrit Biotech As Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
CN1443778A (zh) * 2002-03-13 2003-09-24 上海中信国健药业有限公司 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物
US20060140983A1 (en) * 2004-10-25 2006-06-29 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
WO2007016340A2 (en) * 2005-07-29 2007-02-08 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
EP1951318B1 (en) * 2005-11-07 2012-10-17 British Columbia Cancer Agency Inhibition of autophagy genes in cancer chemotherapy
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP2630968A1 (en) * 2006-06-30 2013-08-28 Baylor Research Institute Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells
AR060424A1 (es) 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same
CN105288602A (zh) 2011-10-20 2016-02-03 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗

Also Published As

Publication number Publication date
IL232173A0 (en) 2014-06-30
NZ623917A (en) 2016-09-30
SG11201401631VA (en) 2014-05-29
WO2013059778A3 (en) 2013-07-04
EP2768534A4 (en) 2015-04-01
KR20150004791A (ko) 2015-01-13
EP2768534A1 (en) 2014-08-27
JP2014530627A (ja) 2014-11-20
JP2014533938A (ja) 2014-12-18
HK1201175A1 (en) 2015-08-28
NZ623915A (en) 2016-02-26
SG10201602424RA (en) 2016-05-30
EP2768519A2 (en) 2014-08-27
WO2013059784A1 (en) 2013-04-25
SG10201508535RA (en) 2015-11-27
US9555058B2 (en) 2017-01-31
SG11201401632WA (en) 2014-05-29
CA2852960A1 (en) 2013-04-25
CN105288602A (zh) 2016-02-03
CN103917246A (zh) 2014-07-09
US20140308316A1 (en) 2014-10-16
CN103957925A (zh) 2014-07-30
CN105861437A (zh) 2016-08-17
CA2852967A1 (en) 2013-04-25
EP2768519A4 (en) 2015-07-01
WO2013059778A2 (en) 2013-04-25
CN105999249A (zh) 2016-10-12
IL232172A0 (en) 2014-06-30
AU2012325758A1 (en) 2014-04-24
KR20150016200A (ko) 2015-02-11
US20140314814A1 (en) 2014-10-23
AU2012325764A1 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
HK1201175A1 (en) Antigen presenting cancer vaccine with gamma interferon
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
TN2015000050A1 (en) Methods of treating a tauopathy
AU2012222463A8 (en) Cea antibodies
IL266131A (en) Compositions for reprogramming cells into dendritic cells or antigen-presenting cells, methods and uses thereof
EP3194577A4 (en) Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
CL2012003299A1 (es) Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma.
WO2013177429A3 (en) Extreme pcr
EP4461824A3 (en) Detection kit or device and detection method for biliary tract cancer
HK1226299A1 (zh) 用於诱发免疫反应的组合物、方法及工具
MX2014006630A (es) Vacuna a base toxina clostridium difficile.
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2011156690A3 (en) Methods for the development of vaccines based on oligosaccharide-oligonucleotide conjugates
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
EP2831101A4 (en) LOADED NUTRIENT FRAGMENTS, PROTEINS AND METHOD
WO2013082249A3 (en) Compositions and methods for prostate cancer analysis
AU2017268198A1 (en) Anti-factor ix padua antibodies
EP3516057A4 (en) METHOD FOR GENOTYPING HUMAN LEUKOCYTE ANTIGEN AND DETERMINING HAPLOTYP DIVERSITY IN A POPULATION
HK1202432A1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
MX2016017136A (es) Composiciones y metodos para detectar pegivirus 2 de humano (hpgv-2).
WO2012177930A8 (en) System for handling biological samples
WO2009114816A3 (en) Therapeutic cancer antigens
SG11201610200RA (en) Method for producing tolerogenic dendritic cells with specific antigens and uses thereof
WO2012019125A3 (en) Biomarkers for prostate cancer and methods for their detection